Amgen’s Post

View organization page for Amgen

1,368,393 followers

We proudly recognize Simon Jackson and Chadwick (Chad) King, recipients of Amgen’s prestigious George B. Rathmann Award for Scientific Excellence, for their groundbreaking work unlocking the potential of PCSK9 biology in LDL regulation and cardiovascular disease. Their journey from decoding the complexities of human genetics to delivering life-changing medicine reflects the very essence of our mission: to serve patients. 🔗 Learn more about their inspiring story: https://amgen.ly/42oSlSS

  • No alternative text description for this image
Miriam O'Sullivan

Executive Director Plant Manager of Manufacturing Amgen

2mo

Well deserved recognition for amazing work

Like
Reply
Monica Florio

Director/Sr PTL, Cardiometabolic Disorders at Amgen

2mo

Congrats 🎉 Your discovery of key mechanistic aspects of PCSK9 biology and development of this therapeutic have been a real game changer for atherosclerosis patients.

Simon Clowes

Lifecycle Leader and Franchise Lead Cardiovascular

2mo

Congrats ! So very well deserved, simply the best !

Like
Reply
Ahsan Tonoy

Epitaxy Process Integration Engineering Technician | Engineers turn dreams into reality

2mo

You guys are doing amazing!!!

Like
Reply
Don Harbart

Founding Partner, Business Transformation and Organization Design at Pajaro Partners LLC

2mo

Congratulations!

Like
Reply

Congrats Simon and Chad - this has made such a huge impact on patient lives!

Mark Ellis

Global Marketing Director, General Medicine, Amgen

2mo

Congratulations!

Like
Reply
Rati Verma

Principal Scientist at Amgen

2mo

Congratulations on having your breakthrough work recognized Simon & Chad! 👏🏽👏🏽

Like
Reply
James Dettore

Chairman & CEO at Brand Institute

2mo

Congratulations on receiving Amgen’s prestigious George B. Rathmann Award for Scientific Excellence!

Like
Reply

Congratulations Simon and Chad! Well done gents. 👏 Truly groundbreaking work that will change lives.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics